Attovia Therapeutics Upsized IPO Pricing
Analysis based on 17 articles · First reported Aug 05, 2026 · Last updated Aug 06, 2026
The IPO provides Attovia with approximately $289 million in gross proceeds to fund its clinical development programs, strengthening its balance sheet and supporting pipeline advancement. The successful pricing and upsizing reflect investor confidence in the biotech sector and may positively influence sentiment for similar clinical-stage companies.
Attovia Therapeutics, a clinical-stage biopharmaceutical company, priced its upsized initial public offering of 17,000,000 shares of common stock at $17.00 per share, expecting gross proceeds of $289.0 million. The offering was upsized from an earlier plan, and the company granted underwriters a 30-day option to purchase up to an additional 2,550,000 shares. Trading on the Nasdaq Global Market Global Market under the symbol ATTO began on August 5, 2026, with the offering expected to close on August 6, 2026. Morgan Stanley, Leerink Partners, Citigroup, and Royal Bank of Canada — RBC Capital Markets acted as joint book-running managers, with LifeSci Capital as passive book-running manager. The registration statement was declared effective by the United States — United States Securities and Exchange Commission on August 4, 2026. Attovia develops biotherapeutics for immune-mediated diseases using its ATTOBODY platform, with lead programs including ATTO-1310, ATTO-2306, and ATTO-1091.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard